Literature DB >> 21303708

The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice.

Mengcheng Luo1, Xiao Qu, Ruangang Pan, Dandan Zhu, Yuan Zhang, Jianguo Wu, Zishu Pan.   

Abstract

As an adaptor molecule in the retinoic acid-inducible gene-I (RIG-I) signaling pathway, the virus-induced signaling adaptor (VISA) molecule activates NF-κB and IRF3 and thereby leads to the production of type I interferons (IFNs). To explore the potential of VISA as a genetic adjuvant for DNA vaccines, a eukaryotic expression plasmid, pVISA, was generated by cloning the VISA gene into the pVAX1vector. For comparison, the pTRIF plasmid was similarly constructed, encoding the known genetic adjuvant TRIF (TIR-domain-containing adapter-inducing interferon-β), an adapter in the Toll-like receptor (TLR) signaling pathway. Mice were immunized with the chimeric DNA vaccine pHA/NP(147-155), which encodes the HA (hemagglutinin) fused with NP (nucleoprotein) CTL epitope (NP(147-155)) of H5N1 influenza virus, either alone or in combination with pVISA or pTRIF. Antigen-specific immune responses were examined in immunized mice. Our results demonstrate that co-immunization of the pHA/NP(147-155) plasmid with the VISA adjuvant augmented DNA-raised cellular immune responses and provided protection against H5N1 influenza virus challenge in mice. In addition, our data suggest that VISA acts as a stronger adjuvant for DNA immunization than TRIF. We conclude that co-inoculation with a vector expressing the adaptor molecule VISA enhanced the protective immunity against H5N1 infection induced by pHA/NP(147-155) and that VISA could be developed as a novel genetic adjuvant for DNA vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303708     DOI: 10.1016/j.vaccine.2011.01.060

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Oral Delivery of a Novel Attenuated Salmonella Vaccine Expressing Influenza A Virus Proteins Protects Mice against H5N1 and H1N1 Viral Infection.

Authors:  Zenglin Pei; Xiaohong Jiang; Zhu Yang; Xiaoguang Ren; Hao Gong; Michael Reeves; Jingxue Sheng; Yu Wang; Zishu Pan; Fenyong Liu; Jianguo Wu; Sangwei Lu
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

Review 2.  Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases.

Authors:  Thomas Grunwald; Sebastian Ulbert
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

Review 3.  DNA Vaccines-How Far From Clinical Use?

Authors:  Dominika Hobernik; Matthias Bros
Journal:  Int J Mol Sci       Date:  2018-11-15       Impact factor: 5.923

4.  MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens.

Authors:  Matthias Liniger; Artur Summerfield; Nicolas Ruggli
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

5.  Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine.

Authors:  Dennis Lapuente; Viktoria Stab; Michael Storcksdieck Genannt Bonsmann; Andre Maaske; Mario Köster; Han Xiao; Christina Ehrhardt; Matthias Tenbusch
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

6.  A systematic review of SARS-CoV-2 vaccine candidates.

Authors:  Yetian Dong; Tong Dai; Yujun Wei; Long Zhang; Min Zheng; Fangfang Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-10-13

Review 7.  The impact of immuno-aging on SARS-CoV-2 vaccine development.

Authors:  Jennifer Connors; Matthew R Bell; Jennifer Marcy; Michele Kutzler; Elias K Haddad
Journal:  Geroscience       Date:  2021-02-11       Impact factor: 7.713

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.